Shares of TESARO Inc (NASDAQ:TSRO) are super hot today today on Ovarian Cancer results and the rally could continue to be hot until phase 3 results in the fall. The stock is up at the time of this written by over $40, 110%, destroying the shorts (at least for today). The sell side are panicing to play catch up with price targets here is what they are saying.
This morning TESARO Inc (NASDAQ:TSRO reported long-waited Ph3 NOVA data, showing s.s. PFS benefits in both cohorts; plans to file for U.S. & EU approval in 4Q16. Contrary to our cautious stance on non-gBRCAm/HRD+ arm following experts’ discussions, this arm also showed s.s clinically meaningful PFS benefits of ~9mo. AE profile was consistent with Ph1 data (most common Gr3/4 AEs thrombocytopenia, anemia & neutropenia). Full data to be presented at ESMO on 10/7-10/11.
Since its founding by Will Thomson and Chip Russell in June 2016, the Massif Capital Real Asset Strategy has outperformed all of its real asset benchmarks. Since its inception, the long/short equity fund has returned 9% per annum net, compared to 6% for the Bloomberg Commodity Index, 3% for the 3 MSCI USA Infrastructure index Read More
NOVA Results Bode Well Other Studies: The outstanding NOVA results, in our view, bode well for other ongoing and planned studies involving niraparib. We note that other clinical programs involving niraparib continue to progress well: (i) QUADRA, 4th line ovarian; (ii) PRIMA, 1st line ovarian; (iii) BRAVO, BRCA+ breast cancer; and (iv) combination trials involving: (a) niraparib plus KEYTRUDA, triple negative breast cancer and ovarian indications; and AVANOVA – niraparib plus bevacizumab, ovarian cancer.
We expect broad use across ovarian cancer maintenance and niraparib looks clinically